AU2019253569A1 - Compositions and methods for cancer or neoplasia assessment - Google Patents

Compositions and methods for cancer or neoplasia assessment Download PDF

Info

Publication number
AU2019253569A1
AU2019253569A1 AU2019253569A AU2019253569A AU2019253569A1 AU 2019253569 A1 AU2019253569 A1 AU 2019253569A1 AU 2019253569 A AU2019253569 A AU 2019253569A AU 2019253569 A AU2019253569 A AU 2019253569A AU 2019253569 A1 AU2019253569 A1 AU 2019253569A1
Authority
AU
Australia
Prior art keywords
target
methylation
sequencing
kit
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019253569A
Other languages
English (en)
Inventor
Jeffrey A. Gole
Athurva J. GORE
Rui Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Singlera Genomics Inc
Original Assignee
Singlera Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singlera Genomics Inc filed Critical Singlera Genomics Inc
Publication of AU2019253569A1 publication Critical patent/AU2019253569A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/113—PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2019253569A 2018-04-12 2019-04-08 Compositions and methods for cancer or neoplasia assessment Abandoned AU2019253569A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862656820P 2018-04-12 2018-04-12
US62/656,820 2018-04-12
PCT/US2019/026395 WO2019199696A1 (en) 2018-04-12 2019-04-08 Compositions and methods for cancer or neoplasia assessment

Publications (1)

Publication Number Publication Date
AU2019253569A1 true AU2019253569A1 (en) 2020-10-29

Family

ID=68163272

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019253569A Abandoned AU2019253569A1 (en) 2018-04-12 2019-04-08 Compositions and methods for cancer or neoplasia assessment

Country Status (10)

Country Link
US (1) US20210388445A1 (https=)
EP (1) EP3775290A4 (https=)
JP (1) JP2021520809A (https=)
KR (1) KR20210003795A (https=)
CN (1) CN112352057A (https=)
AU (1) AU2019253569A1 (https=)
CA (1) CA3096668A1 (https=)
SG (1) SG11202009866XA (https=)
TW (1) TW202012638A (https=)
WO (1) WO2019199696A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111989407B (zh) 2018-03-13 2024-10-29 格里尔公司 异常的片段检测及分类
CN119753091A (zh) 2018-04-02 2025-04-04 格里尔公司 用于扩增与癌症相关联的cfDNA分子的化验板
IL281741B2 (en) 2018-09-27 2026-04-01 Grail Inc Methylation markers and a targeted methylation detection panel
WO2020132572A1 (en) 2018-12-21 2020-06-25 Grail, Inc. Source of origin deconvolution based on methylation fragments in cell-free-dna samples
US12584177B2 (en) 2019-01-24 2026-03-24 Mayo Foundation For Medical Education And Research Detecting endometrial cancer
US11795495B1 (en) * 2019-10-02 2023-10-24 FOXO Labs Inc. Machine learned epigenetic status estimator
CA3154354A1 (en) * 2019-10-31 2021-05-06 William R. Taylor Detecting ovarian cancer
CN111833965B (zh) * 2019-11-08 2024-06-04 中国科学院北京基因组研究所(国家生物信息中心) 一种尿沉渣基因组dna的分类方法、装置和用途
US20230002832A1 (en) * 2019-11-27 2023-01-05 Keio University Upper urinary tract urothelial carcinoma identification method
IL296453A (en) * 2020-03-20 2022-11-01 Singlera Health Tech Shanghai Ltd Methods and kits for screening colorectal neoplasm
EP4419714A4 (en) * 2021-11-23 2025-02-26 Pleno, Inc. CODED DOSAGES
CN118451202A (zh) * 2021-12-20 2024-08-06 江苏鹍远生物技术有限公司 一种肿瘤检测方法及应用
CN114959038B (zh) * 2022-06-13 2024-12-17 湖南宏雅基因技术有限公司 一种hoxa9基因甲基化检测试剂及其应用
CN117766028B (zh) * 2022-09-16 2025-03-11 深圳吉因加医学检验实验室 一种基于甲基化差异预测样本来源的方法及装置
WO2024117791A1 (ko) 2022-11-29 2024-06-06 주식회사 지씨지놈 식도암 및 위암 진단용 dna 메틸화 마커 및 이의 용도
WO2024137858A2 (en) * 2022-12-22 2024-06-27 Singlera Genomics Inc. Methods and compositions for assessing colorectal cancer
EP4669776A1 (en) * 2023-02-22 2025-12-31 University of Southern California EARLY PAN-CANCER DETECTION AND CFDNA METHYLATION IN THE CONTEXT OF MINIMAL RESIDUAL DISEASE
WO2025203031A2 (en) * 2024-03-26 2025-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of cancer detection by discordant methylation in cfdna

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1942197A1 (de) * 2000-09-01 2008-07-09 Epigenomics AG Verfahren zur Bestimmung des Methylierungsgrades von bestimmten Cytosinen in genomischer DNA im Sequenzkontext 5'-CpG-3'
CN104846092A (zh) * 2007-02-21 2015-08-19 奥斯陆大学医院Hf 新型癌症标记物
US20100297067A1 (en) * 2007-05-14 2010-11-25 The Johns Hopkins University Methylation markers for prostate cancer and methods of use
US7843254B2 (en) * 2007-10-31 2010-11-30 Texas Instruments Incorporated Methods and apparatus to produce fully isolated NPN-based bandgap reference
WO2009108917A2 (en) * 2008-02-29 2009-09-03 Oncomethylome Sciences, S.A. Markers for improved detection of breast cancer
US20110223180A1 (en) * 2010-03-11 2011-09-15 Aldape Kenneth D Methods and compositions related to a multi-methylation assay to predict patient outcome
AU2013262435B2 (en) * 2012-05-18 2019-03-07 Clinical Genomics Pty. Ltd. A method of screening for colorectal cancer
CN105339507A (zh) * 2013-02-21 2016-02-17 托马生物科学公司 用于核酸分析的方法、组合物和试剂盒
EP2886659A1 (en) * 2013-12-20 2015-06-24 AIT Austrian Institute of Technology GmbH Gene methylation based colorectal cancer diagnosis
EP3224377B1 (en) * 2014-11-25 2020-01-01 AIT Austrian Institute of Technology GmbH Diagnosis of lung cancer
US9984201B2 (en) * 2015-01-18 2018-05-29 Youhealth Biotech, Limited Method and system for determining cancer status
WO2016138105A2 (en) * 2015-02-24 2016-09-01 Zymo Research Corporation Assays to determine dna methylation and dna methylation markers of cancer
EP3350344A1 (en) * 2015-09-17 2018-07-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cancer detection methods
CN116064796A (zh) * 2016-05-05 2023-05-05 精密科学公司 通过分析甲基化dna来检测肺肿瘤

Also Published As

Publication number Publication date
CN112352057A (zh) 2021-02-09
SG11202009866XA (en) 2020-11-27
US20210388445A1 (en) 2021-12-16
EP3775290A1 (en) 2021-02-17
CA3096668A1 (en) 2019-10-17
TW202012638A (zh) 2020-04-01
EP3775290A4 (en) 2021-12-29
WO2019199696A1 (en) 2019-10-17
JP2021520809A (ja) 2021-08-26
KR20210003795A (ko) 2021-01-12

Similar Documents

Publication Publication Date Title
US20210388445A1 (en) Compositions and methods for cancer and neoplasia assessment
US11965157B2 (en) Compositions and methods for library construction and sequence analysis
US10072283B2 (en) Direct capture, amplification and sequencing of target DNA using immobilized primers
US20200048697A1 (en) Compositions and methods for detection of genomic variance and DNA methylation status
EP4428244B1 (en) Methods and compositions for analyzing nucleic acid
US10465241B2 (en) High resolution STR analysis using next generation sequencing
JPWO2019199696A5 (https=)
JP2024529674A (ja) 同時での変異検出およびメチル化分析のための方法
WO2024137858A2 (en) Methods and compositions for assessing colorectal cancer
HK40041271A (en) Compositions and methods for cancer or neoplasia assessment
WO2025178881A1 (en) Methods and compositions for assessing tissue and organ damage
US20260071273A1 (en) Methods for nucleic acid sequencing

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted